These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 36547753

  • 1. Identification of potential inhibitors of Mycobacterium tuberculosis shikimate kinase: molecular docking, in silico toxicity and in vitro experiments.
    Freitas de Freitas T, Roth CD, Abbadi BL, Hopf FSM, Perelló MA, de Matos Czeczot A, de Souza EV, Borsoi AF, Machado P, Bizarro CV, Basso LA, Timmers LFSM.
    J Comput Aided Mol Des; 2023 Mar; 37(3):117-128. PubMed ID: 36547753
    [Abstract] [Full Text] [Related]

  • 2. Identification of novel antimicrobial compounds targeting Mycobacterium tuberculosis shikimate kinase using in silico hierarchical structure-based drug screening.
    Kawamoto S, Hori C, Taniguchi H, Okubo S, Aoki S.
    Tuberculosis (Edinb); 2023 Jul; 141():102362. PubMed ID: 37311288
    [Abstract] [Full Text] [Related]

  • 3. Screening of antitubercular compound library identifies novel shikimate kinase inhibitors of Mycobacterium tuberculosis.
    Rajput VS, Mehra R, Kumar S, Nargotra A, Singh PP, Khan IA.
    Appl Microbiol Biotechnol; 2016 Jun; 100(12):5415-26. PubMed ID: 26887318
    [Abstract] [Full Text] [Related]

  • 4. Benzothiazole Derivative as a Novel Mycobacterium tuberculosis Shikimate Kinase Inhibitor: Identification and Elucidation of Its Allosteric Mode of Inhibition.
    Mehra R, Rajput VS, Gupta M, Chib R, Kumar A, Wazir P, Khan IA, Nargotra A.
    J Chem Inf Model; 2016 May 23; 56(5):930-40. PubMed ID: 27149193
    [Abstract] [Full Text] [Related]

  • 5. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
    Simithy J, Reeve N, Hobrath JV, Reynolds RC, Calderón AI.
    Tuberculosis (Edinb); 2014 Mar 23; 94(2):152-8. PubMed ID: 24429106
    [Abstract] [Full Text] [Related]

  • 6. Toxicological Profiling of Potential Shikimate Kinase Inhibitors Against Mycobacterium tuberculosis.
    Jhangiani A, Panda V, Sukheja A, Thomas S, Dusseja P, Pandya S, Chintakrindi A.
    Altern Lab Anim; 2024 Jan 23; 52(1):10-27. PubMed ID: 38095084
    [Abstract] [Full Text] [Related]

  • 7. Shikimate Kinase Inhibitors: An Update on Promising Strategy against Mycobacterium tuberculosis.
    Rajput VS, Runthala A, Khan IA.
    Curr Drug Targets; 2023 Jan 23; 24(5):388-405. PubMed ID: 36752299
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in silico evaluations of actinomycin X2and actinomycin D as potent anti-tuberculosis agents.
    Qureshi KA, Azam F, Fatmi MQ, Imtiaz M, Prajapati DK, Rai PK, Jaremko M, Emwas AH, Elhassan GO.
    PeerJ; 2023 Jan 23; 11():e14502. PubMed ID: 36935926
    [Abstract] [Full Text] [Related]

  • 9. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R, Zahra NU, Azam SS.
    Comput Biol Chem; 2019 Apr 23; 79():91-102. PubMed ID: 30743161
    [Abstract] [Full Text] [Related]

  • 10. Selective Mycobacterium tuberculosis Shikimate Kinase Inhibitors as Potential Antibacterials.
    Gordon S, Simithy J, Goodwin DC, Calderón AI.
    Perspect Medicin Chem; 2015 Apr 23; 7():9-20. PubMed ID: 25861218
    [Abstract] [Full Text] [Related]

  • 11. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H.
    Curr Pharm Des; 2014 Apr 23; 20(27):4305-6. PubMed ID: 24245755
    [Abstract] [Full Text] [Related]

  • 12. Structure-based Discovery of Narirutin as a Shikimate kinase Inhibitor with Anti-tubercular Potency.
    Sahu PK, Mohapatra PK, Rajani DP, Raval MK.
    Curr Comput Aided Drug Des; 2020 Apr 23; 16(5):523-529. PubMed ID: 31654517
    [Abstract] [Full Text] [Related]

  • 13. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against Mycobacterium tuberculosis.
    Venugopala KN, Tratrat C, Pillay M, Chandrashekharappa S, Al-Attraqchi OHA, Aldhubiab BE, Attimarad M, Alwassil OI, Nair AB, Sreeharsha N, Venugopala R, Morsy MA, Haroun M, Kumalo HM, Odhav B, Mlisana K.
    Drug Des Devel Ther; 2020 Apr 23; 14():1027-1039. PubMed ID: 32214795
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone.
    Simithy J, Fuanta NR, Hobrath JV, Kochanowska-Karamyan A, Hamann MT, Goodwin DC, Calderón AI.
    Biochim Biophys Acta Proteins Proteom; 2018 Apr 23; 1866(5-6):731-739. PubMed ID: 29654976
    [Abstract] [Full Text] [Related]

  • 15. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN, Deb PK, Pillay M, Chopra D, Chandrashekharappa S, Morsy MA, Aldhubiab BE, Attimarad M, Nair AB, Sreeharsha N, Kandeel M, Venugopala R, Mohanlall V.
    Curr Top Med Chem; 2021 Apr 23; 21(4):295-306. PubMed ID: 33138763
    [Abstract] [Full Text] [Related]

  • 16. Molecular modeling and docking studies of O-succinylbenzoate synthase of M. tuberculosis--a potential target for antituberculosis drug design.
    Pulaganti M, Banaganapalli B, Mulakayala C, Chitta SK, C M A.
    Appl Biochem Biotechnol; 2014 Feb 23; 172(3):1407-32. PubMed ID: 24203275
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Identification of new potential Mycobacterium tuberculosis shikimate kinase inhibitors through molecular docking simulations.
    Vianna CP, de Azevedo WF.
    J Mol Model; 2012 Feb 23; 18(2):755-64. PubMed ID: 21594693
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
    Dwivedi M, Mukhopadhyay S, Yadav S, Dubey KD.
    Comput Biol Med; 2022 Jul 23; 146():105607. PubMed ID: 35617724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.